Supply Chain Intelligence

Enanta Pharmaceuticals, Inc. Supply Chain

ENTA supply chain intelligence for Enanta Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ENTA ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

1Suppliers
4Customers
2Debt Items
20Related Chains

Enanta Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
ABBVIE-INC ABBVIE-INC 90% Under the agreement, we have granted AbbVie an exclusive, worldwide, royalty-bearing license, including a right to grant sublicenses, to specified intellectual property, including several issued U.S.…

Enanta Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
ABBVIE-INC ABBVIE-INC 92% AbbVie is responsible for and has funded all costs associated with the development, manufacturing and commercialization of paritaprevir, glecaprevir and any other compounds under this agreement.
OMERS OMERS 92% In April 2023, the Company entered into a royalty sale agreement with an affiliate of OMERS, pursuant to which the Company was paid a $ 200,000 cash purchase price in exchange for 54.5 % of future qu…
ABT Abbott Laboratories 90% We entered into a Collaborative Development and License Agreement with Abbott Laboratories in November 2006 to develop and commercialize HCV NS3 and NS3/4A protease inhibitors.
ABT Abbott Laboratories 90% Reciprocal relationship from ABT graph: Reciprocal relationship from ENTA graph: We entered into a Collaborative Development and License Agreement with Abbott Laboratories in November 2006 to develop…

Enanta Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ENTA-DEBT Debt stack $186.6M 90% Market cache reports total debt of $186.6M.
ENTA-DEBT-9316 Xbrl Convertible 90% xbrl convertible detail from xbrl 2013-09-30.

Enanta Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
ENTA-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 133 tracked holders.

Enanta Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
MTLS Materialise NV 100.00 2
NVS Novartis AG 100.00 2
IVA Inventiva S.A. 100.00 2
IINN Inspira Technologies Oxy B.H.N. Ltd. 100.00 2
GRAL GRAIL, Inc. 100.00 2
NBP NovaBridge Biosciences 100.00 2
GIFOF Grifols, S.A. 100.00 2
ITGR Integer Holdings Corporation 100.00 2
ALVO Alvotech 100.00 2
GIFLF Grifols, S.A. 100.00 2
PSNL Personalis, Inc. 100.00 2
VTAK Catheter Precision, Inc. 100.00 2
GCTK GlucoTrack, Inc. 100.00 2
GRFS Grifols, S.A. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
FLGT Fulgent Genetics, Inc. 100.00 2
AORT Artivion, Inc. 100.00 2
GIKLY Grifols, S.A. 100.00 2
EXAS Exact Sciences Corp 100.00 2
NSPR InspireMD, Inc. 100.00 2
View ENTA supply chain intel →

Explore the full interactive supply chain map for Enanta Pharmaceuticals, Inc..

Open ENTA supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map